BillionDollarBreaks Archive - BillionDollarClub

ThursdayAug 13, 2026 9:30 am

BillionDollarBreaks – G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF) Reports Q2 Revenue of $157.1 Million, Maintains 2026 Gold Production Guidance

This article has been disseminated on behalf of G Mining Ventures Corp. and may include paid advertising. G Mining Ventures Corp. (TSX: GMIN) (OTCQX: GMINF) reported second-quarter 2026 revenue of $157.1 million on sales of 37,439 ounces of gold at an average realized price of $4,197 per ounce. Gold production totaled 36,845 ounces, up 16% sequentially, while net income reached $72 million, or $0.30 per basic share, and free cash flow totaled $84.8 million. The company ended the quarter with $225.7 million in cash and cash equivalents and $33 million in long-term debt, resulting in a net cash position of…

MondayAug 10, 2026 3:00 pm

BillionDollarBreaks – Forward Industries Inc. (NASDAQ: FWDI) Expands Solana Holdings and Institutional Capital Access

Forward Industries (NASDAQ: FWDI) expanded its Solana treasury by more than 500,000 SOL during fiscal Q3 2026 at an average purchase price of approximately $79 per SOL, bringing its holdings to 7.55 million SOL as of June 30. The company also sold 93,642 shares through its at-the-market offering while reporting 36% annualized SOL-per-share growth, which it says demonstrates its ability to raise capital in an accretive manner. Following inclusion in the Russell 2000 and Russell 3000 indexes, Forward says it has additional access to institutional capital, while its proprietary fwdSOL staking token provides another source of liquidity. To view the full…

WednesdayJul 29, 2026 1:31 pm

BillionDollarBreaks – Forward Industries Inc. (NASDAQ: FWDI) Building SOL-Focused Platform with Active On-Chain Strategy

Forward Industries (NASDAQ: FWDI) is building a Solana-focused treasury platform designed to generate value through active participation in the Solana ecosystem, including staking, lending and decentralized finance. The company currently holds more than 7 million SOL, while its validator infrastructure has generated gross annual yields of approximately 6.5% to 7.2% before fees, and roughly 25% of its SOL holdings are represented by its proprietary liquid staking token, fwdSOL. Forward has also announced a letter of intent and made an offer to acquire the Solana Company, which it believes could create value through greater scale and combined Solana expertise. To view the…

WednesdayJul 29, 2026 9:00 am

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Expands Patent Portfolio to Support Next-Generation Cancer Therapy Platforms

VERAXA Biotech (NASDAQ: VRXA) announced an expansion of its intellectual property portfolio, filing new patent applications during the first half of 2026 covering its next-generation BiTAC-TCE and BiTAC-ADC technology platforms and related therapeutic programs. The company said previously granted patents protecting supporting technologies have also cleared the opposition period, bringing its portfolio to more than 50 granted owned or exclusively licensed patents across 14 countries and 26 patent families. Pending approval of the latest filings, VERAXA expects its core technologies to be protected through at least 2047. The company said its BiTAC platform is designed to improve the selectivity and…

MondayJul 27, 2026 11:46 am

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures

VERAXA Biotech (NASDAQ: VRXA) announced that shareholders overwhelmingly approved all proposals presented at its Extraordinary General Meeting, with more than 99.94% of votes cast in favor and 72.20% of the company's outstanding share capital represented. The approved measures include the introduction of conditional share capital for shareholder options and warrants, implementation of a capital band through Dec. 31, 2030 and an increase in the maximum size of the board of directors from five to seven members. The company said the enhanced corporate and financing framework is intended to support its long-term growth strategy by providing greater flexibility for potential acquisitions, strategic collaborations, investment projects, capital…

MondayJul 27, 2026 11:31 am

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration

VERAXA Biotech (NASDAQ: VRXA) announced the advancement of its bispecific antibody-drug conjugate ("bsADC") program, VXA-222, after reaching a key technical milestone in its collaboration with OmniAb (NASDAQ: OABI). The company said OmniAb has successfully completed its discovery work, allowing the program to move into its next phase. VXA-222 is designed to target two tumor antigens with a single molecule using an "AND-gate" approach intended to improve precision in treating solid tumors. Under the collaboration launched in May 2025, OmniAb provided antibody discovery technologies, including its OmniClic(TM) platform, while VERAXA is applying its proprietary linker technology and conjugation expertise to develop and validate the lead bsADC candidate. VERAXA holds exclusive rights to develop and commercialize…

ThursdayJul 23, 2026 9:30 am

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer

VERAXA Biotech (NASDAQ: VRXA) announced the appointment of Christoph Erkel, Ph.D., as chief scientific officer, effective immediately. Erkel, previously vice president of research and development, will lead advancement of the company's proprietary BiTAC(R) platform technologies for the development of cancer therapies targeting solid tumors. He succeeds Rick Austin, Ph.D., who will depart following a transition period. Erkel brings two decades of experience in antibody therapeutics, antibody engineering and preclinical development, including prior leadership roles at MorphoSys AG, where he led immuno-oncology programs focused on T-cell engagers. VERAXA said his experience managing multidisciplinary research programs will support efforts to expand the…

MondayJul 20, 2026 9:30 am

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform

VERAXA Biotech (NASDAQ: VRXA) announced it has received Scientific Advice from Germany's Paul-Ehrlich-Institute regarding the underlying biology and proposed non-clinical development plan for its lead proprietary BiTAC-TCE cancer therapy program. The company said the regulatory feedback provides greater clarity on its proposed development strategy and indicates that the agency understands the biological rationale behind its dual-targeting, conditionally active BiTAC-TCE platform, representing an early step in advancing the program toward clinical development. VERAXA also highlighted preclinical data presented at the American Association for Cancer Research Annual Meeting 2026 showing its lead BiTAC-TCE candidate selectively targeted cancer cells expressing both intended targets…

MondayJul 13, 2026 9:30 am

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Development

VERAXA Biotech (NASDAQ: VRXA) announced a collaboration with AI-driven bioinformatics company Ardigen S.A. to support development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates. The partnership will initially focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA's BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity. VERAXA said integrating artificial intelligence into its research and development strategy could enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity. The company believes the collaboration will strengthen development of precision…

MondayJul 13, 2026 9:00 am

BillionDollarBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Appoints Carl von Halem Interim Chief Financial Officer

VERAXA Biotech (NASDAQ: VRXA) announced the appointment of Carl von Halem as interim chief financial officer, succeeding Torsten Bürgermeister. The company said it is in the final stages of discussions with a permanent CFO candidate expected to support its next phase of expansion and operational growth, with an update to be provided in due course. Von Halem currently serves as chief financial officer of Xlife Sciences and played a key role in VERAXA's public listing. The company cited his experience in corporate finance, life sciences and technology-driven businesses, as well as his familiarity with VERAXA's operations and strategic development, as…

The exclusive home of the biggest and brightest companies covered by IBN.

Contact us: (512) 354-7000

GreenEnergyNewsBreaks